镇心痛口服液联合单硝酸异山梨酯治疗冠心病心绞痛的临床研究  

Clinical study of Zhenxintong Oral Liquid combined with isosorbide mononitrate in treatment of angina pectoris

作　　者：王璇[1] 余诣涵 陈阵[3] WANG Xuan;YU Yihan;CHEN Zhen(Department of Cardiology,Wuhan Traditional Chinese Medicine Hospital,Wuhan 430000,China;Hubei University,Wuhan 430000,China;Department of Cardiology,Wuhan Central Hospital,Wuhan 430014,China)

机构地区：[1]武汉市中医医院心内科,湖北武汉430000 [2]湖北大学,湖北武汉430000 [3]武汉市中心医院心内科,湖北武汉430014

出　　处：《现代药物与临床》2024年第7期1786-1791,共6页Drugs & Clinic

基　　金：湖北省自然科学基金资助项目(2022CFC002)。

摘　　要：目的 探讨镇心痛口服液联合单硝酸异山梨酯治疗冠心病心绞痛的临床疗效。方法 选取2022年7月—2023年10月武汉市中医医院收治的86例冠心病心绞痛患者,依据用药情况将所有患者分为对照组和治疗组,每组各43例。对照组患者口服单硝酸异山梨酯缓释片,40 mg/次,1次/d。治疗组在对照组的治疗基础上口服镇心痛口服液,20 mL/次,3次/d。两组用药12周观察治疗情况。观察两组的临床疗效和症状缓解时间,比较两组治疗前后西雅图心绞痛评分量表(SAQ)评分、欧洲五维健康生活质量问卷量表(EQ-5D)评分、血管性假血友病因子(vWF)、同型半胱氨酸(Hcy)、一氧化氮(NO)、P-选择素水平的变化情况。结果 治疗后,治疗组总有效率是95.35%,显著高于对照组的79.07%(P<0.05)。治疗后,治疗组患者胸闷、胸痛、心悸、体力不支缓解时间均显著短于对照组(P<0.05)。治疗后,两组心绞痛持续时间、发作次数均较同组治疗前显著降低(P<0.05);治疗后,治疗组心绞痛持续时间、发作次数均低于对照组(P<0.05)。治疗后,两组SAQ评分、EQ-5D评分均显著提高(P<0.05);治疗后,治疗组SAQ评分、EQ-5D评分均高于对照组(P<0.05)。治疗后,两组血清Hcy、vWF、P-选择素水平均显著降低,而NO显著升高(P<0.05);治疗后,治疗组Hcy、vWF、P-选择素水平均低于对照组,NO水平高于对照组(P<0.05)。结论 镇心痛口服液联合单硝酸异山梨酯治疗冠心病心绞痛具有较好的临床疗效,能有效改善患者临床症状,减弱机体炎性反应,提升患者生活质量,值得借鉴与应用。Objective To investigate the therapeutic effect of Zhenxintong Oral Liquid combined with isosorbide mononitrate in treatment of angina pectoris. Methods A total of 86 patients with angina pectoris with coronary heart disease admitted to Wuhan Traditional Chinese Medicine Hospital from July 2022 to October 2023 were selected. According to drug use, all patients were divided into control group and treatment group, with 43 cases in each group. Patients in control group were po administered with Isosorbide Mononitrate Sustained-Release Tablets, 40 mg/time, once daily. Patients in treatment group were po administered with Zhenxintong Oral Liquid on the basis of the control group, 20 mL/time, three times daily. The two groups were treated for 12 weeks to observe the treatment. The clinical efficacy and symptom remission time of two groups were observed, and the changes of the Seattle Angina Rating Scale (SAQ) score, the European five-dimension Health Quality of Life Questionnaire (EQ-5D) score, vascular pseudomelophiliac factor (vWF), homocysteine (Hcy), nitric oxide (NO), and P-selectin levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 95.35%, which was significantly higher than that of control group (79.07%, P < 0.05). After treatment, the relief time of chest tightness, chest pain, palpitation and physical inactivity in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, the duration and frequency of angina pectoris in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the duration and frequency of angina pectoris in treatment group were lower than those in control group (P < 0.05). After treatment, SAQ score and EQ-5D score were significantly increased in both groups (P < 0.05). After treatment, SAQ scores and EQ-5D scores in treatment group were higher than those in control group (P < 0.05). After treatment, serum Hcy, vWF and P-sele

关 键 词：镇心痛口服液 单硝酸异山梨酯缓释片 冠心病心绞痛 心绞痛持续时间 心绞痛发作次数 西雅图心绞痛评分量表评分 欧洲五维健康生活质量问卷量表评分 血管性假血友病因子 同型半胱氨酸 一氧化氮 

分 类 号：R972[医药卫生—药品]